News

Latest news
October 31, 2024

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO,...

October 30, 2024

Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; These Results Include an Unfavorable Impact of...

October 29, 2024

SkinSpirit will make a kick-off donation and offer clients the ability to donate directly to Girls Inc. from November 1 – 15th IRVINE, Calif., Oct. 29, 2024 /PRNewswire/ -- In its sixth year of...

More »

AbbVie on Twitter

Looking for more news from AbbVie? Follow us on social media.

News

Advanced Search
Our history

Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more

Societal impact

Our commitment to science is a commitment to better our society. Read our 2023 ESG report

Ratings and recognition

We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more

Annual report

See our latest 2023 Annual Report on Form 10-K. Learn more

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?